Alpha Teknova (NASDAQ:TKNO) Releases Earnings Results, Meets Expectations

Alpha Teknova (NASDAQ:TKNO) released its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09), FiscalAI reports. The business had revenue of $9.98 million during the quarter, compared to analysts’ expectations of $9.62 million. Alpha Teknova had a negative net margin of 45.78% and a negative return on equity of 23.53%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Solid 2025 operational and financial progress — revenue grew 7% to $45.0M, Q4 revenue was $10.0M, gross margin improved to ~33%, adjusted EBITDA loss narrowed to -$6.7M, and free cash outflow improved to -$9.8M with $21.3M in cash on hand.
• Clinical Solutions momentum — the company now serves 60 clinical customers (up from 48), supports ~70 therapies (5 in Phase 2+ and 12 in Phase 1), and expects to support at least one commercial therapy by end-2027, with commercialization potentially driving large per-therapy spend increases (~30x from early-phase levels).
• Targeted investment and path to profitability — management will add about $2M/year in commercial spend to pursue sequencing, spatial genomics, and cancer-screening customers, guides 2026 revenue to $42M–$44M, and targets adjusted EBITDA positivity by end-2027 at roughly $52M–$57M annualized revenue.
• Near-term risk and sensitivity to biotech funding and timing — management warns of a ~4-quarter lag from biotech funding to revenue, lower average revenue per customer from new additions, and potential quarter-to-quarter lumpiness from large Clinical Solutions orders, leaving 2026 upside contingent on market recovery and customer ramps.

Alpha Teknova Stock Performance

Shares of Alpha Teknova stock traded up $0.02 on Thursday, hitting $2.28. The stock had a trading volume of 172,211 shares, compared to its average volume of 345,704. The company has a quick ratio of 4.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.18. Alpha Teknova has a 52-week low of $1.91 and a 52-week high of $7.48. The company’s 50 day moving average price is $3.18 and its 200 day moving average price is $4.28.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Zacks Research raised Alpha Teknova to a “hold” rating in a report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Teknova in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Alpha Teknova

Several large investors have recently modified their holdings of TKNO. Marshall Wace LLP boosted its stake in Alpha Teknova by 83.0% during the 2nd quarter. Marshall Wace LLP now owns 90,032 shares of the company’s stock worth $442,000 after purchasing an additional 40,825 shares during the period. Wexford Capital LP purchased a new stake in shares of Alpha Teknova in the third quarter valued at about $306,000. Jane Street Group LLC acquired a new stake in shares of Alpha Teknova during the fourth quarter worth about $239,000. PharVision Advisers LLC grew its holdings in shares of Alpha Teknova by 103.5% during the third quarter. PharVision Advisers LLC now owns 37,645 shares of the company’s stock worth $233,000 after buying an additional 19,149 shares during the last quarter. Finally, National Bank of Canada FI purchased a new position in shares of Alpha Teknova during the third quarter worth about $148,000. 13.81% of the stock is owned by institutional investors and hedge funds.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.